Moderna's Stock Rises 0.35% on Sept. 24 as $0.19 Billion Volume Ranks 495th in Market Activity

Moderna (MRNA) rose 0.35% on Sept. 24, with a trading volume of $0.19 billion, ranking it 495th in market activity. The biotech firm’s stock movement reflected investor focus on its clinical pipeline and regulatory developments. Analysts noted that recent updates on its mRNA-based therapies for infectious diseases and cancer reinforced its long-term growth potential, though short-term volatility remained tied to production capacity and clinical trial timelines.

Investor sentiment was cautiously optimistic, driven by renewed interest in the company’s collaboration with academic institutions to expand its R&D footprint. While no immediate catalysts emerged in the form of trial approvals or partnership announcements, the stock’s performance aligned with broader market trends in the biotech sector, which saw modest gains amid speculation about upcoming FDA guidance on mRNA therapeutics.

To run this back-test accurately, I need to pin down a few practical details: 1. Market universe • Do you want all U.S.–listed common stocks (NYSE + NASDAQ + AMEX), or a different universe? 2. “Top 500 stocks by daily trading volume” • Rank by share volume or by dollar volume (volume × price)? • Re-rank every trading day? 3. Trade execution conventions • Buy at the day’s close and sell at the next day’s close (a one-day overnight hold), or buy at next day’s open and sell at the same day’s close (an intraday hold)? • Equal-weight each position (i.e., 1/500 of capital per stock)? 4. Transaction costs • Assume zero costs/slippage, or apply a per-side commission or bid-ask spread? 5. Risk controls • Any stop-loss / take-profit / maximum drawdown you would like to enforce, or simple buy-and-hold-for-one-day per position? Once I have these points, I’ll generate the data-retrieval plan and run the back-test.